App-Quantinova.ai

Risk factors and prognostic impact of venous thromboembolism (VTE) in patients (pts) with advanced gastric cancer (AGC).

Hiroyuki Arai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Edoxaban

Expression of programmed death-ligand 1 (PD-L1), mismatch repair status, and Epstein-Barr status in locally advanced gastric adenocarcinoma: Correlation to clinical outcome.

Krishna Patel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical significance of preoperative chemoradiotherapy for advanced esophageal cancer patients using propensity score matching.

Yoshinori Fujiwara - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Definitive chemoradiation with carboplatin and paclitaxel in locally advanced esophageal carcinoma: A retrospective analysis at the Brazilian National Cancer Institute (INCA).

Kelly Borges Araujo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC).

Laura Toppo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pegfilgrastim

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).

Annette Van Zweeden - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Prognostic role of body-mass index at diagnosis in gastric cancer: a systematic review and meta-analysis.

Sashidhar Manthravadi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Population-based analysis of hospital readmissions within 1 year of esophagectomy.

Biniam Kidane - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of vitamin K dosing during sorafenib treatment for hepatocellular carcinoma: Effect on ischemic tumor cell damage caused by sorafenib.

Yoshimichi Haruna - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

Contribution of eukaryotic translation initiation factor 3B to the pathogenesis of hepatocellular carcinoma via targeting EGFR and ZAK.

Jian-Feng Zheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Role of diffusion weighted magnetic resonance imaging in evaluation of response to chemotherapy in gall bladder carcinoma.

Lavdeep Singh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Translating a clinical trial to daily practice: Outcome of palliative treatment in patients with advanced cholangiocarcinoma and gallbladder cancer in the Netherlands.

Joeri Dierks - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Preclinical characterization of GNS561 as a novel first in class autophagy inhibitor to kill hepatocellular carcinoma cancer stem cells.

Firas Bassissi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

GNS561

Predictors of sorafenib efficacy in treated patients with hepatocellular carcinoma: A tertiary cancer center experience.

Kanaan Alshammari - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

The density of cancer-associated fibroblasts as a prognostic indicator for hepatocellular carcinoma.

Tian Tian Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A CNV computational model for clonal origin analysis of synchronous multifocal hepatobiliary and pancreatic tumors.

Weiqin Jiang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparison of a new prognostic system and six current staging systems in predicting the survival rate of patients with advanced hepatocellular carcinoma undergoing loco-regional therapy.

Ying-Fen Hong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinicopathologic and prognostic features of hepatocellular carcinoma (HCC) due to metabolic syndrome (MS) compared to chronic liver disease (CLD) and cryptogenic causes (CC).

Matthew L Chase - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Solid malignancies

N/A

The prognostic impact of proinflammatory markers (NLR, PLR) in biliary cancer.

Leslie Jane Padrnos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy and cost-effectiveness of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.

Qiu Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

Filters

41730 Abstracts